Skip to main content
Sarepta Therapeutics, Inc. logo

Sarepta Therapeutics, Inc. — Investor Relations & Filings

Ticker · SRPT ISIN · US8036071004 LEI · 549300IKDPIED8J8IG21 US Manufacturing
Open in API
Filings indexed 1,061 across all filing types
Latest filing 2021-11-17 Board/Management Inform…
Country US United States of America
Listing US SRPT

About Sarepta Therapeutics, Inc.

https://www.sarepta.com/

Sarepta Therapeutics is a commercial-stage biopharmaceutical company that engineers precision genetic medicines for rare diseases. The company's research and development efforts are centered on RNA-targeted therapeutics and gene therapies, with a primary focus on treating rare neuromuscular and central nervous system disorders. Sarepta aims to accelerate the drug development process from discovery to patient application and is building significant gene therapy manufacturing capabilities to support its mission.

Recent filings

Filing Released Lang Actions
8-K
Board/Management Information Classification · 100% confidence The document is a Form 8-K filed with the SEC, which is a Current Report used to announce major events that shareholders should know about. The content specifically details changes in the company's board of directors and senior management, including the appointment of a new director, promotion of an officer, and departure of another officer. There are no financial statements or detailed financial data present, and the focus is on management changes. According to the filing definitions, announcements of changes in the company's board or senior management fall under Board/Management Information (MANG). Therefore, the correct classification is MANG with high confidence.
2021-11-17 English
10-Q
Interim / Quarterly Report Q3 2021
2021-11-03 English
8-K
Capital/Financing Update Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events that shareholders should know about. The content includes an underwriting agreement for a public offering of common stock, details about the offering price, number of shares, and net proceeds. It also references press releases announcing preliminary financial results and the offering pricing. There are no comprehensive financial statements or detailed financial analysis typical of an Interim/Quarterly Report (IR) or Annual Report (10-K). The primary focus is on the financing event (public offering) and related agreements. Therefore, this document fits best under the category of Capital/Financing Update (CAP). The document length (6352 characters) and detailed description of the underwriting agreement and offering confirm it is not merely an announcement of a report but a substantive filing about financing activity.
2021-10-15 English
424B5
Capital/Financing Update Classification · 95% confidence The document is a prospectus supplement and accompanying prospectus related to a securities offering by Sarepta Therapeutics, Inc. It includes detailed information about the offering of common stock, underwriting details, risk factors, use of proceeds, and company overview. The document references registration statements and SEC rules (e.g., Rule 424(b)(5)) and is clearly a filing related to capital raising through a stock offering. This type of document is a capital/financing update rather than a financial report, earnings release, or other report type. It is not an announcement of a report publication but the actual offering document. Therefore, the correct classification is Capital/Financing Update (CAP). The document length and content support a high confidence in this classification.
2021-10-15 English
424B5
Capital/Financing Update Classification · 100% confidence The document is a preliminary prospectus supplement dated October 12, 2021, related to a $500 million offering of common stock by Sarepta Therapeutics, Inc. It includes detailed information about the offering terms, risk factors, use of proceeds, underwriting, and legal matters. The document is clearly a registration and offering document filed pursuant to Rule 424(b)(5) under the Securities Act of 1933. It is not a financial report, earnings release, or management discussion, but rather a capital raising document describing the terms and conditions of a stock offering. Therefore, it fits the category of Capital/Financing Update (CAP). The document length (15,000 characters) and content confirm it is a full prospectus supplement, not just an announcement or a brief notice.
2021-10-12 English
8-K
Regulatory Filings Classification · 100% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce unscheduled material events or corporate changes. The text includes a press release about a program update for a clinical study, furnished as an exhibit. There are no financial statements or detailed financial data presented. The document is short (3823 characters) and primarily serves as a regulatory announcement of a press release. It does not contain an annual report, earnings release, or other detailed financial or management reports. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous SEC filings that do not fit other specific categories.
2021-09-27 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.